Lazertinib’s US Approval A Catalyst For Oscotec’s Growth

Anti-Resistance, Anti-Tau Therapies Next Focus

 
• By Jung Won Shin

Oscotec co-CEO Taeyoung Yoon highlights anti-resistance and anti-tau therapies as the Korean bioventure’s next possible blockbuster candidates after the landmark US approval of lazertinib for lung cancer.

Taeyoung Yoon, Oscotec CEO
Long-Term Goal To Grow Into FIPCO With Marketing, Commercial Presence (Oscotec Inc.)

More from Focus On Asia

More from R&D